|
Market Closed -
Toronto S.E.
12:39:18 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | 0.00% |
|
0.00% | -25.00% |
| 07-17 | Waverley Pharma Inc. Announces CFO Changes, Effective July 24, 2026 | CI |
| 05-22 | Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biopharmaceutical Industry | 1.75M | 1.25M | 412K | 475K | 1.35M | |||||
Total Assets | 3.68M | 2.69M | 952K | 2.05M | 1.24M | |||||
Interest Expense | - | - | -76.65K | -163K | -179K | |||||
Income Tax Expense | - | - | - | - | 1.63K | |||||
EBT | -797K | -664K | -2.22M | -947K | -498K | |||||
Gross Profit | 223K | 284K | 79.8K | 214K | 514K | |||||
D&A | 70.25K | 108K | 322K | 24.03K | 83.3K | |||||
Net Income | -797K | -664K | -2.22M | -947K | -499K |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | - | 475K | 1.35M | |||||
Total Assets | - | - | - | 885K | 761K | |||||
United Kingdom (UK) | 1.75M | 1.25M | 412K | - | - | |||||
Total Assets | 1.76M | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
Net Income | - | - | - | - | - | |||||
Total Assets | - | 1.68M | 265K | 265K | - |
- Stock Market
- Stocks
- WAVE Stock
- Financials Waverley Pharma Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
